What the Research Says About Red Light Therapy & Vaginal Dryness

If you've started looking into red light therapy for vaginal dryness, you've probably run into two kinds of content. One promises transformation. The other dismisses the whole category as wellness nonsense.

Neither is very useful when you're the one dealing with it.

So here's a third option: a straight walk through what has actually been published, who was studied, what improved, what didn't, and — the part almost nobody covers — how the equipment used in those studies compares to what you can buy for home use. Some of what follows will sound promising. Some of it should give you pause. Both are true at the same time, and you deserve to see both before you spend money on anything.

First, what we're actually talking about

The clinical term is photobiomodulation, often shortened to PBM. Older literature calls it low-level laser therapy, or LLLT.

The idea is that specific wavelengths of red and near-infrared light, delivered at low intensity, are absorbed by structures inside your cells and prompt a biological response. Crucially, this isn't heat. Unlike the ablative lasers used in some in-office procedures, photobiomodulation is often described as a "cold laser" approach — it aims to trigger cellular activity without thermal injury to tissue.

The proposed mechanism has been worked out in reasonable detail, largely through the work of Michael Hamblin at Massachusetts General Hospital, who is the most-cited researcher in this field. The short version: photons in roughly the 620–700nm range are absorbed by cytochrome c oxidase, an enzyme in the mitochondrial electron transport chain. In stressed or damaged cells, excess nitric oxide binds to that enzyme and suppresses energy production. Red light appears to displace it, restoring the chain and increasing ATP output. Downstream, researchers have observed changes in genes governing collagen production and tissue remodeling, along with signals that promote new blood vessel formation.

That's the theory. It's well-developed and biologically plausible. But a plausible mechanism is not the same as a proven clinical outcome, which is why the studies matter.

[Screenshot: Hamblin, "Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation," Photochemistry and Photobiology, 2018]

Why anyone is studying this for menopause

Vaginal dryness is one symptom of a broader condition clinicians call genitourinary syndrome of menopause, or GSM. It covers dryness, irritation, painful intercourse, and a range of urinary symptoms, all stemming from declining estrogen.

Topical estrogen remains the standard treatment and works well for many women. But it isn't available to everyone. Survivors of hormone-dependent cancers are often advised against it. Some women have other contraindications. And a substantial number simply won't use it, or start and don't continue — long-term compliance in this category is notoriously poor.

That gap is the reason researchers have spent the last decade looking at energy-based alternatives: CO2 lasers, Er:YAG lasers, radiofrequency, and more recently, low-level light.

Worth knowing: the energy-based device category has a mixed track record. A randomized trial published in JAMA in 2021 compared fractional CO2 laser against sham treatment for postmenopausal vaginal symptoms and did not find the benefit the field expected.

The FDA issued a safety communication in 2018 warning about how "vaginal rejuvenation" devices were being marketed. So this is a field where enthusiasm has repeatedly outrun evidence, and it's reasonable to approach new claims with your guard up.

The most relevant study to date

In June 2026, PLOS One published the most directly applicable research so far: a prospective study from National Taiwan University Hospital evaluating photobiomodulation for GSM.

What they did. Twenty-seven postmenopausal women, mean age 62.9, all diagnosed with GSM, were enrolled between January 2024 and July 2025. Each received eight weekly sessions, thirty minutes per session, of pulsed 660nm light delivered through a silicone light-guide probe inserted by a physician. Assessments were taken at baseline, before the fourth session, before the eighth, and again three months after treatment finished.

The primary measure was the Vaginal Health Index, a clinician-assessed score covering elasticity, fluid volume, pH, epithelial integrity, and moisture. Secondary measures used validated questionnaires for urinary symptoms and sexual function.

What improved. The Vaginal Health Index results were the strongest finding. Scores rose significantly at every follow-up point, and every one of the five sub-measures — elasticity, fluid, pH, integrity, moisture — improved. Looking at the proportion of participants who crossed the clinical threshold for non-atrophic tissue: about 41% by the fourth session, 92% by the eighth, and all participants at the three-month follow-up.

Urinary symptoms also improved across several standardized questionnaires, and those gains held at three months. Several quality-of-life domains improved too, including sleep, emotional wellbeing, and social limitation.

No adverse events were reported during the study.

What didn't improve, or didn't clearly. This is the part that gets left out of most summaries, and it's the part that tells you the researchers were being careful.

Sexual function was measured using the Female Sexual Function Index. Total scores did improve in the overall statistical test — but when researchers ran the more conservative pairwise comparisons, that improvement no longer held up. Only about 13% of participants reached the clinical cutoff for resolved sexual dysfunction at the three-month mark. Within the individual domains, orgasm and satisfaction improved robustly. Desire, arousal, and sexual pain all trended upward but did not reach statistical significance.

In other words: the tissue measurably changed. Whether that translated into how women experienced their sex lives was much less clear-cut. The authors offer a thoughtful explanation — that physical repair and psychological recovery may run on different timelines, and three months may simply be too short to see the second one.

The limitations

The authors of this study are notably candid about what their work can and cannot establish, and it would be dishonest of me to summarize their findings without their caveats.

There was no control group. This was a single-arm study — everyone received the treatment, and there was no placebo or comparison arm. That means the improvements observed cannot be cleanly separated from placebo response or natural variation over time. The authors state this plainly and describe their own findings as preliminary and hypothesis-generating. A controlled study is being organized.

That caveat matters enormously in this particular field. The JAMA CO2 laser trial mentioned earlier found that a treatment which looked effective in uncontrolled studies did not outperform sham once a control arm was added. Sham-controlled testing has a way of deflating this category.

The sample was small. Twenty-seven participants gives limited statistical power, particularly for the secondary outcomes.

Follow-up was three months. Nothing here tells us about durability at a year.

A registered randomized, double-blind, placebo-controlled trial of photobiomodulation for GSM is underway (ClinicalTrials.gov NCT05557799), using a different wavelength and applied to the vulvar region. Until results from properly controlled trials are published, the honest position is that this is a promising early signal, not established efficacy.

The part most articles skip: clinical equipment versus home devices

This is the section I most want you to read, because it's where marketing in this category tends to blur things.

The Taiwan study used a physician-operated semiconductor diode laser system. The probe was inserted to the posterior fornix by a clinician and held stationary for thirty minutes to deliver uniform circumferential exposure. The researchers documented their radiometric parameters precisely — irradiance at the probe tip and side, and total energy delivered per session at two anatomical locations.

An at-home device is not that. Consumer devices generally use LEDs rather than laser diodes. Session lengths are shorter. Placement varies with the user rather than being clinician-controlled. And total delivered energy is usually lower — sometimes much lower — than a clinical protocol.

None of these differences are hidden or shameful. But they mean study results should not be assumed to transfer. If a company points at clinical research and implies their at-home product produces those outcomes, that's a claim the research does not support, and you should treat it as a warning sign about everything else they tell you.

What you can reasonably take from the research is narrower, and still worth something: the wavelength range has a documented mechanism, clinical work at 660nm has produced encouraging early signals for tissue-level measures, and the safety profile in studies to date has been favorable.

What you cannot take from it is a guarantee that a device you use at home for ten minutes will reproduce what a clinician achieved in thirty.

What this means if you're considering a device

A few things I'd want a friend to know.

Know what you're buying. Ask any manufacturer for wavelength, whether they use LEDs or laser diodes, and their irradiance figures. Companies with real engineering behind them can answer. Companies that dodge are telling you something.

Understand the regulatory language. "FDA-cleared" and "FDA-approved" have specific meanings, and many at-home wellness devices hold neither — they're marketed under the FDA's general wellness framework, which is a different thing entirely. A product being legally sold does not mean it has been evaluated for effectiveness. If a company uses "approved" loosely, that's worth noticing.

Expect cumulative, not immediate. Every protocol in the literature runs for weeks. The Taiwan study took eight sessions before most participants crossed the tissue threshold. Anything promising a fast fix is not describing how this works.

Treat it as one part of a bigger picture. An at-home wellness device is not a substitute for talking to a healthcare provider. If dryness or pain is affecting your life, that's a conversation worth having, and there are options — topical estrogen, non-hormonal prescriptions, pelvic floor physical therapy — that a device doesn't replace.

Watch for overclaiming. In a field where a well-run RCT has already contradicted an entire device category once, anyone telling you their product cures, treats, or reverses anything is going beyond what anybody currently knows.

How to raise it with your doctor

If you want to bring this up at your next appointment, something like this works:

"I've been having vaginal dryness and discomfort. I'm not able to use / would prefer not to use hormones. What are my options, and is there anything you'd suggest I avoid?"

And if you're specifically considering a device:

"I'm looking at an at-home red light therapy device for intimate wellness. Is there any reason that wouldn't be appropriate for me?"

Worth asking about: local vaginal estrogen (which has a different risk profile from systemic hormone therapy — the two are commonly confused), non-hormonal prescription options, and pelvic floor physical therapy, which is underused in the US and genuinely effective for many women.

Frequently asked questions

Does red light therapy work for vaginal dryness? Early clinical research is encouraging but not conclusive. A 2026 prospective study of 27 women found significant improvements in clinician-assessed vaginal health measures after eight weekly 660nm sessions. However, the study had no control group, and the authors describe their findings as preliminary. Controlled trials are still needed.

What wavelength did the studies use? The 2026 Taiwan study used pulsed 660nm light. A registered randomized trial currently underway uses 808nm applied to the vulvar region. Red light in the roughly 620–700nm range is where most of the mechanism research sits.

How is an at-home device different from what researchers used? Substantially. Clinical studies use physician-operated laser systems with documented energy output, held in place for 30-minute sessions. Home devices typically use LEDs, run shorter sessions, and deliver less total energy. Study results should not be assumed to apply to consumer products.

How long did it take to see changes in the research? Improvements appeared progressively. About 41% of participants reached the clinical threshold for non-atrophic tissue by the fourth weekly session, 92% by the eighth, and all by the three-month follow-up. Light therapy is cumulative in every published protocol.

Is it a replacement for vaginal estrogen? No. Topical estrogen remains a standard, well-evidenced treatment. Research into photobiomodulation is motivated by the fact that some women cannot use hormones or choose not to — not by evidence that it performs equivalently. That comparison hasn't been made.

Is it safe? No adverse events were reported in the 2026 study, and participants generally found the procedure comfortable. That said, safety findings from supervised clinical settings don't automatically extend to unsupervised home use. Anyone with a history of pelvic malignancy, an active infection, or who is pregnant should speak to a provider first.

Does it help with urinary symptoms? The 2026 study did find improvements across several urinary symptom questionnaires that persisted at three months. The same caveat applies — no control group, small sample. Urinary symptoms should be evaluated by a healthcare provider rather than self-managed.

What should I ask before buying any device? Wavelength, LED or laser, irradiance figures, regulatory status in precise terms, session protocol, return policy, and whether the company will show you the research they're relying on.

Sources

• Wu P-C, Lin H-H, Chen C-H, Kuo Y-S. Evaluation of photobiomodulation therapy for genitourinary syndrome of menopause: A single-center prospective study. PLOS One, 22 June 2026. DOI: 10.1371/journal.pone.0351765

• Hamblin MR. Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation. Photochemistry and Photobiology, 2018.

• de Freitas LF, Hamblin MR. Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy. IEEE Journal of Selected Topics in Quantum Electronics, 2016.

• Li FG et al. Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial. JAMA, 2021.

• Photobiomodulation in post-menopause genitourinary syndrome. ClinicalTrials.gov NCT05557799.

• Phillips NA, Bachmann GA. The genitourinary syndrome of menopause. Menopause, 2021.